

INTERIM TECHNICAL UPDATE

TECHNICAL AND OPERATIONAL
CONSIDERATIONS FOR

IMPLEMENTING HIV VIRAL LOAD TESTING

JULY 2014

ACCESS TO HIV DIAGNOSTICS



WHO Library Cataloguing-in-Publication Data:

Technical and operational considerations for implementing HIV viral load testing: interim technical update.

1.HIV Infections - diagnosis. 2.Anti-Retroviral Agents – pharmacology. 3.Viral Load. 4.HIV Infections – drug therapy. 5.National Health Programs. I.World Health Organization. II.Centers for Disease Control and Prevention (U.S.). III.United States. Agency for International Development. IV.Global Fund to Fight AIDS, Tuberculosis and Malaria. V.African Society for Laboratory Medicine.

ISBN 978 92 4 150757 8

(NLM classification: WC 503.1)

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The mark "CDC" is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise.

Cover photo: Ms. Lucy Kithinji, KEMRI

TECHNICAL AND OPERATIONAL CONSIDERATIONS FOR IMPLEMENTING HIV VIRAL LOAD TESTING

INTERIM TECHNICAL UPDATE – JULY 2014

TABLE OF CONTENTS

Acknowledgements	3
Abbreviations	4
Executive summary	5
Introduction	6
PHASE 1: Planning	7
Policies, leadership and government commitment.....	7
Harmonization.....	7
Developing a clinical algorithm for viral load monitoring.....	7
Mapping and forecasting the viral load testing network.....	8
Viral load testing network.....	8
Assessing capacity for viral load testing.....	9
Costing viral load testing.....	9
Specimen type and product selection.....	9
Operational characteristics of viral load technologies.....	11
Procuring equipment.....	13
PHASE 2: Scale-up	14
Phasing in viral load monitoring.....	14
Human resources.....	14
Training and supervision.....	15
Quality management system.....	16
PHASE 3: Sustainability – maintaining a viral load testing network	18
Harmonization among partners and implementing partners.....	18
Monitoring and evaluation and information systems.....	18
Data collection and analysis.....	19
Ongoing operational research.....	19
References	20
ANNEX 1. Strategic planning framework for implementing viral load testing of the African Society for Laboratory Medicine	21
ANNEX 2. Summary of commercially available HIV viral load testing technologies based on nucleic acid testing	22
ANNEX 3. Sample request form for requisitioning specimens for viral load testing	24

ACKNOWLEDGEMENTS

This document is a multi-partner effort and has been prepared by the United States Centers for Disease Control and Prevention, the Office of the United States Global AIDS Coordinator/United States President's Emergency Plan for AIDS Relief, the United States Agency for International Development, the WHO Department of HIV/AIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the African Society for Laboratory Medicine. In addition, several external key partners have contributed to the report, including: Johns Hopkins University; Cheikh Anta Diop University; the Bill & Melinda Gates Foundation; Clinton Health Access Initiative; Ministry of Health, Kenya; Ministry of Health, Uganda; and Ministry of Health and Social Welfare, United Republic of Tanzania; and the WHO Prequalification of In Vitro Diagnostics Programme. Original data are presented from external organizations, including the United States Centers for Disease Control and Prevention and the South African National Health Laboratory Service.

ABBREVIATIONS

ART	antiretroviral therapy
CAP	College of American Pathologists
CD4	cluster of differentiation 4
CE	European conformity
EDTA	ethylenediaminetetraacetic acid
IVD	in vitro diagnostic medical device
PCR	polymerase chain reaction
SLIPTA	Stepwise Laboratory Quality Improvement Process towards Accreditation
SLMTA	Strengthening Laboratory Management towards Accreditation
TB	tuberculosis

EXECUTIVE SUMMARY

This publication provides high-level guidance on implementing and scaling up HIV viral load testing programmes for health ministries and implementation partners, using a three-phased approach: (1) planning; (2) scale-up; and (3) sustainability. The guidelines for managing antiretroviral therapy (ART) issued by WHO have recognized the importance of viral load monitoring since 2003. Routine viral load monitoring is now strongly recommended as the monitoring strategy of choice. In 2013, WHO recommended viral load as the preferred monitoring approach to diagnose and confirm ART failure and using the reduced threshold of viral failure of 1000 copies/ml based on two consecutive viral load measurements using plasma specimens within 12 months, with adherence support between measurements. There are many challenges to implementing viral load monitoring

in resource-limited settings, including complex technical requirements to perform the test, the logistics of specimen transport and cost. This publication addresses strategies to plan and implement a logical viral load testing network, including engaging leadership, mapping and forecasting, product and specimen selection, algorithm development, human resources and infrastructure requirements, monitoring and evaluation, maintenance, quality management systems and training. A key inclusion is technical guidance on using dried blood spot specimens. This publication is intended to serve as a reference point for countries, whether they are commencing implementation or scaling up existing viral load testing capacity. Thoughtful consideration and planning of all areas covered in this publication will assist in developing a robust and sustainable HIV viral load testing network.

INTRODUCTION

The 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1) recommend viral load testing as the preferred monitoring tool for diagnosing and confirming the failure of antiretroviral therapy (ART). In accordance with these guidelines, many countries are investing in viral load testing to monitor people receiving ART (Fig. 1). Viral load monitoring is the gold standard practice in resource-rich countries for detecting treatment failure among people receiving ART; however, its availability in resource-limited settings has been severely restricted because of prohibitively high costs (US\$ 40–85 per test solely for reagents and consumables), complex specimen collection and transport requirements and the need for well-established laboratory infrastructure and well-trained personnel. Because of these financial and operational barriers, the WHO treatment guidelines, while recognising viral load as the gold standard for ART monitoring, have historically focused on using clinical and immunological criteria for determining treatment failure. However,

numerous studies have demonstrated the poor predictive value of the WHO immunological criteria for identifying viral failure and have shown that delayed detection of treatment failure leads to accumulation of HIV drug resistance (2,3). The 2013 WHO consolidated antiretroviral guidelines (1) recommend viral load testing six months after initiating ART and then annually for people receiving ART; for the people with detectable viraemia, targeted adherence support followed by confirmatory viral load testing is recommended to distinguish poor adherence from true treatment failure. Those with treatment failure would then be switched to second-line ART.

This publication provides high-level guidance on implementing and scaling up viral load testing programmes for health ministries and implementing partners. It aims to inform national HIV programme managers and laboratory managers using a three-phased approach: (1) planning; (2) scale-up; and (3) sustainability.

Fig. 1. Phased implementation of viral load testing



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27807

